E Paul Larrat
Overview
Explore the profile of E Paul Larrat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ye Y, Larrat E, Caffrey A
Ther Adv Cardiovasc Dis
. 2017 Dec;
12(2):39-51.
PMID: 29224509
Drug-induced QT interval prolongation may increase the risk of sudden cardiac death or ventricular arrhythmias (SCD/VA), and therefore affects the safety profile of medications. Administrative databases can be used to...
2.
Larrat E, Marcoux R, Vogenberg F
P T
. 2014 Mar;
39(2):126-8.
PMID: 24669180
Legislative and regulatory efforts to address controlled substance diversion and overuse of narcotics are affecting prescription drug utilization and patient care. These initiatives can influence formulary drug selection, prior authorization...
3.
Marcoux R, Larrat E, Vogenberg F
P T
. 2014 Jan;
38(10):612-9.
PMID: 24391380
State policies vary regarding the legal use of marijuana for medicinal purposes. Pharmacists, physicians, and P&T committee members must become familiar with the laws in their states before assuming that...
4.
Alshammari T, Larrat E, Morrill H, Caffrey A, Quilliam B, LaPlante K
Am J Health Syst Pharm
. 2013 Dec;
71(1):37-43.
PMID: 24352180
Purpose: Results of a pharmacoepidemiologic evaluation of fluoroquinolone-associated hepatotoxicity using national hospital admissions data on Veterans Affairs (VA) patients are reported. Methods: In a retrospective case-control study, all adults with...
5.
Larrat E, Marcoux R, Vogenberg F
P T
. 2013 May;
38(3):164-5.
PMID: 23641136
Among the health care changes this year: revenues to hospitals will be lower, payments to physicians will be modified, and more patients will be covered by Medicaid.
6.
Marcoux R, Larrat E, Vogenberg F
P T
. 2012 Dec;
37(11):629-50.
PMID: 23204817
The ACO model is considered an important achievement of health care reform legislation. However, ACOs might not be able to deliver on their promises in part because of the slowly...
7.
Vogenberg F, Marcoux R, Larrat E
Consult Pharm
. 2012 Sep;
27(9):641-9.
PMID: 22982748
Currently, Medicare Part D is the primary payer of pharmaceuticals and driver of formulary selection for most seniors, regardless of their care setting. This primer examines key issues in reimbursement...
8.
Larrat E, Marcoux R, Vogenberg F
P T
. 2012 May;
37(4):218-26.
PMID: 22593634
No abstract available.
9.
Marcoux R, Simeone J, Colavita M, Larrat E
J Correct Health Care
. 2011 Oct;
18(1):53-61.
PMID: 22013144
Numerous models are employed for medication distribution and pharmacy services management in correctional facilities. Since 2003, the University of Rhode Island College of Pharmacy and the Rhode Island Department of...
10.
Kogut S, Andrade S, Willey C, Larrat E
Pharmacoepidemiol Drug Saf
. 2004 Sep;
13(9):591-8.
PMID: 15362081
Purpose: To determine if nonadherence with antidiabetic drug therapy is predictive of subsequent antidiabetic drug therapy intensification. Methods: We conducted a retrospective cohort study examining retail pharmacy dispensings of sulfonylureas...